Jump to ContentJump to Main Navigation
Show Summary Details

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR 2015: 2.710
Rank 142 out of 289 in category Biochemistry & Molecular Biology in the 2015 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 1.607
Source Normalized Impact per Paper (SNIP) 2015: 0.751
Impact per Publication (IPP) 2015: 2.609

Online
ISSN
1437-4315
See all formats and pricing
Volume 389, Issue 5 (May 2008)

Issues

Japanese encephalitis vaccines – needs, flaws and achievements

Erich Tauber
  • 1Intercell AG, Campus Vienna Biocenter 2, A-1030 Vienna, Austria
/ Shailesh Dewasthaly
  • 2Intercell AG, Campus Vienna Biocenter 2, A-1030 Vienna, Austria
Published Online: 2008-03-27 | DOI: https://doi.org/10.1515/BC.2008.062

Abstract

Japanese encephalitis causes serious health problems in countries in Southeast Asia, where the causative virus is endemic. Whereas most adults living in this region have acquired immunity, children are at high risk of infection. Childhood mass immunization programs with first-generation mouse brain-derived vaccines efficiently reduced Japanese encephalitis incidence in affected countries, but immunization recommendations have mostly been abolished in Japan owing to the occurrence of severe side effects. Thus, there is a pressing need for safer vaccines to keep the disease under control. The safety profile of the current vaccines, together with the relatively low incidence, makes the risk/benefit ratio unfavorable for immunization of travelers to Southeast Asia, despite the high mortality once the clinical disease has developed. As Asian countries become increasingly popular travel destinations, the availability of well-tolerated vaccines would likely shift the ratio towards immunization. Currently, there is one second-generation inactivated cell-culture-grown vaccine in late-stage clinical development that is approaching licensing in developed countries.

Keywords: flavivirus; IC51; immunogenicity; Southeast Asia

About the article

Corresponding author


Published Online: 2008-03-27

Published in Print: 2008-05-01


Citation Information: Biological Chemistry, ISSN (Online) 14374315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2008.062. Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Tobias E. Erlanger, Svenja Weiss, Jennifer Keiser, Jürg Utzinger, and Karin Wiedenmayer
Emerging Infectious Diseases, 2009, Volume 15, Number 1, Page 1

Comments (0)

Please log in or register to comment.
Log in